Navigation Links
Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
Date:2/9/2009

SCHAUMBURG, Ill., Feb. 9 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections, in a 500mg single-dose vial.

The 500mg single-dose vial expands Sagent's existing line of Cefazolin products beyond the 1g single-dose vials and 10g pharmacy bulk package vials launched in March 2008. All doses are completely latex-free and include enhanced packaging features such as bar-coding and labeling designed to reduce confusion among doses.

"The innovative labeling we brought to our other Cefazolin products is now available on a 500 mg single-use vial, allowing clinicians access to an extended line of Cefazolin for injection designed with medication safety in mind," said Lorin Drake vice president of sales and marketing at Sagent Pharmaceuticals. "Our enhanced Cefazolin packaging designs incorporate specific features in response to needs expressed by our customers. We are proud to provide practical solutions designed to improve the safety and care of patients in the dose sizes most needed."

Sagent will begin marketing and shipping Cefazolin in the 500mg single-dose vials immediately.

About Cefazolin

Cefazolin for injection, USP, is the generic equivalent of KEFZOL(R), an antibiotic used to treat bacterial infections. Cefazolin for injection, USP, is indicated for serious infections such as those of the respiratory, biliary and urinary tracts, skin and skin structure infections, bone and joint infections, and other infections caused by E. coli, S. pneumoniae, S. aureus, and various strains of streptococci. Prophylactic Cefazolin for injection, USP, preoperative, intraopertative and postoperative administration can be effective in reducing the incidence of certain surgical infections. The most common adverse e
'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
6. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
(Date:1/14/2014)... January 14, 2014 BioMedomics, Inc. , ... POC diagnostic platforms and novel disease specific POC tests, announced ... financing netting a total of $690,000. The investment is from ... the company. This group of private investors has significant successful ...
(Date:1/14/2014)... Translational Biosciences, a subsidiary of ... trial approval for the treatment of rheumatoid arthritis ... from the Comité Nacional de Bioética de la ... (RA) is an autoimmune disease in which the ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... -- Sinovac Biotech Ltd.,(NYSE Alternext US: SVA), ... today,announced its wholly owned subsidiary, Tangshan Yian ... China,s Ministry of Agriculture to,conduct field trials ... with independent intellectual property rights. With this ...
... 26 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... efficacy portion of its initial Phase 3 clinical,trial evaluating ... acute treatment of migraine. , ... potential to be,both fast acting and long-lasting, providing pain ...
... second of its "next-generation" health and longevity products ... cardiovascular healthNEW YORK, Jan. 26 AIM Pharmakon, ... the introduction of the next generation of health ... premium-quality liquid calcium mineral concentrate for bone development ...
Cached Biology Technology:Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 2MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 2AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 4
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... Sexual selection refers to species, selection for traits ... type of natural selection enhances opportunities to mate, the ... Biologists at the University of California, Riverside have now ... of a placenta are linked. Describing the life ... the family Poeciliidae, the researchers found that species with ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... from the Andes in Colombia to the Atlantic in ... plains of the Llanos and the Guiana shield ... 3rd most important river system on the planet, and one of ... has shown a strong commitment to the achievement of the ...
... citizens negotiated the tensions following the March 4 nationwide ... 2007 vote weighed heavily for many reasons. Among those ... of a new paper in AIDS Reviews , ... do to public health by disrupting treatment and thereby ...
... is an exotic plant originating from the Ukraine and ... Ontario, Canada. It has been found growing successfully in ... edges and understories, parks, road edges and railway embankments. ... large and dense stands that climb over other plants. ...
Cached Biology News:The natural ecosystems in the Colombian Orinoco Basin are in danger 2Political strife undermines HIV treatment 2Political strife undermines HIV treatment 3A European invader outcompetes Canadian plants even outside its usual temperature range 2
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... returned to customer conjugation of peptide to KLH protein , ... 102 days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each ...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: